Lysophospholipids: Their generation, physiological role and detection. Are they important disease markers?

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 3, 2009, Pages 368-378

  Fuchs, Beate ^a   Schiller, Jürgen ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Disease markers; Inflammation; Lysophosphatidylcholine; Lysophospholipids; Phospholipase; Phospholipids; Reactive oxygen species; Signaling molecules

Indexed keywords

ANTIINFLAMMATORY AGENT; FLAVONOID; G PROTEIN COUPLED RECEPTOR; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDYLCHOLINE; LYSOPHOSPHOLIPID; OXIDIZED LOW DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE; SPHINGOSINE 1 PHOSPHATE; BIOLOGICAL MARKER;

ASTHMA; ATHEROSCLEROSIS; DIABETES MELLITUS; DIAGNOSTIC VALUE; DISEASE MARKER; ENDOMETRIOSIS; FLUORESCENCE SPECTROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERLIPIDEMIA; IMMUNOMODULATION; INFLAMMATION; ISCHEMIA; KIDNEY FAILURE; LIPID ANALYSIS; LIPID PEROXIDATION; LIPOGENESIS; NEUTROPHIL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OVARY CANCER; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; RHINITIS; SEPSIS; THIN LAYER CHROMATOGRAPHY; ULTRAVIOLET SPECTROSCOPY; ANIMAL; CHEMICAL STRUCTURE; LIPID METABOLISM; METABOLISM; PHYSIOLOGY;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; INFLAMMATION; LIPID METABOLISM; LYSOPHOSPHOLIPIDS; MOLECULAR STRUCTURE; REACTIVE OXYGEN SPECIES;

EID: 65349149053     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389557510909030368     Document Type: Review

References (80)

1. Larsson, K.; Sato, K.; Tiberg, F. Lipids: Structure, Physical Properties and Functionality, The Oily Press Lipid Library: Bridgwater, 2006.
2. Stryer, L. Biochemie, Vieweg: Braunschweig, 1988.
3. Gunstone, F.D.; Phospholipid Technology and Applications, The Oily Press Lipid Library: Bridgwater, 2008.
4. Billich, A.; Baumruker, T. Sphingolipid metabolizing enzymes as novel therapeutic targets. Subcell. Biochem.,2008, 49, 487-522.
5. Wymann, M.P.; Schneiter, R. Lipid signalling in disease. Nat. Rev. Mol. Cell. Biol., 2008, 9, 162-76.
6. Kaiser, E. Phospholipase A2: its usefulness in laboratory diagnostics. Clin. Lab., 1999, 36, 65-163.
7. 2 enzymes: Classification and characterization. Biochim. Biophys. Acta, 2000, 1488, 1-19.
8. Seilhamer, J.J.; Pruzanski, W.; Vadas, P.; Plant, S.; Miller, J.A.; Kloss, J.; Johnson, L.K. Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid. J. Biol. Chem., 1989, 264, 5335-8.
9. 31P NMR and MALDI-TOF MS. Clin. Biochem., 2005, 38, 925-33.
10. Matsumoto, T.; Kobayashi, T.; Kamata, K. Role of lysophosphatidylcholine (LPC) in atherosclerosis. Curr. Med. Chem., 2007, 14, 3209-20.
11. Hammerschmidt, S.; Büchler, N.; Wahn, H. Tissue lipid peroxidation and reduced glutathione depletion in hypochlorite-induced lung injury. Chest, 2002, 121, 573-81.
12. Schiller, J.; Fuchs, B.; Arnhold, J.; Arnold, K. Contribution of reactive oxygen species to cartilage degradation in rheumatic diseases: molecular pathways, diagnosis and potential therapeutic strategies. Curr. Med. Chem., 2003, 10, 2123-45.
13. Koppenol, W.H. The centennial of the Fenton reaction. Free Radic. Biol. Med., 1993, 15, 645-51.
14. Fuchs, B.; Schober, C.; Richter, G.; Nimptsch, A.; Süß, R.; Schiller, J. The Reactions between HOCl and differently saturated phospholipids: Physiological relevance, products and methods of evaluation. Mini-Rev. Org. Chem., 2008, 5, 254-61.
15. Malle, E.; Furtmüller, P.G.; Sattler, W.; Obinger, C. Myeloperoxidase: a target for new drug development? Br. J. Pharmacol., 2007, 152, 838-54.
16. Halliwell, B. Reactive oxygen species in living systems: source, biochemistry, and role in human disease. Am. J. Med., 1991, 91, 14S-22S.
17. 2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis. Med. Sci. Monit., 2006, 12, RA5-16.
18. Arnhold, J.; Osipov, A.N.; Spalteholz, H.; Panasenko, O.M.; Schiller, J. Effects of hypochlorous acid on unsaturated phosphatidylcholines. Free Radic. Biol. Med., 2001, 31, 1111-9.
19. Arnhold, J.; Osipov, A.N.; Spalteholz, H.; Panasenko, O.M.; Schiller, J. Formation of lysophospholipids from unsaturated phosphatidylcholines under the influence of hypochlorous acid. Biochim. Biophys. Acta, 2002, 1572, 91-100.
20. 31P NMR. J. Lipid Res., 2001, 42, 1501-8.
21. Zschörnig, O.; Bergmeier, C.; Süß, R.; Arnold, K.; Schiller, J. Human low-density lipoprotein oxidation: Hypochlorous acid leads to the generation of lysophospholipids under acidic conditions. Lett. Org. Chem., 2004, 1, 381-90.
22. Richter, G.; Schober, C.; Süß, R.; Fuchs, B.; Birkemeyer, C.; Schiller J. Comparison of the positive and negative ion electrospray ionization and matrix-assisted laser desorption ionization-time-of-flight mass spectra of the reaction products of phosphatidylethanolamines and hypochlorous acid. Anal. Biochem., 2008, 376, 157-9.
23. Leßig, J., Fuchs, B. Plasmalogens in Biological systems: their role in oxidative processes in Biological membranes and their contribution to pathological processes and aging. Curr. Med. Chem., submited.
24. Zuidam, N.J.; Gouw, H.K.; Barenholz, Y.; Crommelin, D.J. Physical (in) stability of liposomes upon chemical hydrolysis: the role of lysophospholipids and fatty acids. Biochim. Biophys. Acta, 1995, 1240, 101-10.
25. Hernández-Caselles, T.; Villalaín, J.; Gómez-Fernández, J.C. Stability of liposomes on long term storage. J. Pharm. Pharmacol., 1990, 42, 397-400.
26. Christie, W.W. Lipid Analysis 3rd ed, The Oily Press Lipid Library: Bridgwater, 2003.
27. van den Bosch, H.; Aarsman, A.J. A review on methods of phospholipase A determination. Agents Actions, 1979, 9, 382-9.
28. Aarsman, A.J.; van Deenen, L.L.M.; van den Bosch, H. Studies on lysophospholipases: VII. Synthesis of acylthioester analogs of lysolecithin and their use in a continuous spectrophotometric assay for lysophospholipases, a method with potential applicability to other lipolytic enzymes. Bioorg. Chem., 1976, 5, 241-53.
29. Rawyler, A.; Siegenthaler, P.A. A single and continuous spectrophotometric assay for various lipolytic enzymes, using natural, non-labelled lipid substrates. Biochim. Biophys. Acta, 1989, 1004, 337-44.
30. Peterson, B.L.; Cummings, B.S. A review of chromatographic methods for the assessment of phospholipids in biological samples. Biomed. Chromatogr., 2006, 20, 227-43.
31. Hostetler, K,Y.; Gardner, M.F.; Aldern, K.A. Assay of phospholipases C and D in presence of other lipid hydrolases. Methods Enzymol., 1991, 197, 125-34.
32. 2 and 1-alkylglycerophosphocholine acetyltransferase activities in stimulated alveolar macrophages by HPLC analysis of NBD-labeled ether lipids. Chem. Phys. Lipids, 1996, 79, 29-37.
33. 2. Anal. Biochem., 1988, 172, 397-402.
34. Welsh, C.J.; Schmeichel, K. Assays for investigations of signal transduction mechanisms involving phospholipase D: mass measurements of phosphatidate, phosphatidylethanol, and diacylglycerol in cultured cells. Anal. Biochem., 1991, 192, 281-92.
35. 2 by capillary electrophoresis. J. Chromatogr. A, 1999, 853, 285-93.
36. Catz, S.D.; Sterin-Speziale, N.B. Bradykinin stimulates phosphoinositide turnover and phospholipase C but not phospholipase D and NADPH oxidase in human neutrophils. J. Leukoc. Biol., 1996, 59, 591-7.
37. 31P NMR spectroscopy to the characterization of the phospholipid composition of tissues and body fluids - a methodological review. Med. Sci. Monit., 2002, 8, MT205-22.
38. 31P NMR spectroscopy of phospholipids: From micelles to membranes. Curr. Anal. Chem., 2007, 3, 283-301.
39. Schiller, J.; Süß, R.; Arnhold, J.; Fuchs, B.; Leßig, J.; Müller, M.; Petković, M.; Spalteholz, H.; Zschörnig, O.; Arnold, K. Matrix-assisted laser desorption and ionization time-of-flight (MALDI-TOF) mass spectrometry in lipid and phospholipid research. Prog. Lipid Res., 2004, 43, 449-88.
40. Fuchs, B.; Arnold, K.; Schiller, J. In Encyclopedia of Analytical Chemistry; Meyers, Ed.; John Wiley & Sons Ltd.: Chichester, 2008; Vol 1, pp. 1-39.
41. 2 using fast atom bombardment mass spectrometry. Bioorg. Med. Chem. Lett., 1999, 9, 337-40.
42. Koivusalo, M.; Haimi, P.; Heikinheimo, L.; Kostiainen, R.; Somerharju, P. Quantitative determination of phospholipid compositions by ESI-MS: effects of acyl chain length, unsaturation, and lipid concentration on instrument response. J. Lipid Res., 2001, 42, 663-72.
43. Liebisch, G.; Drobnik, W.; Lieser, B.; Schmitz, G. High-throughput quantification of lysophosphatidylcholine by electrospray ionization tandem mass spectrometry. Clin. Chem., 2002, 48, 2217-24.
44. Pang, L.Q.; Liang, Q.L.; Wang, Y.M.; Ping, L.; Luo, G.A. Simultaneous determination and quantification of seven major phospholipid classes in human blood using normal-phase liquid chromatography coupled with electrospray mass spectrometry and the application in diabetes nephropathy. J. Chromatogr., 2008, 869, 118-25.
45. Pulfer, M.; Murphy, R.C. Electrospray mass spectrometry of phospholipids. Mass Spectrom. Rev., 2003, 22, 332-64.
46. 2. Anal. Biochem., 2002, 308, 61-70.
47. Petković, M.; Schiller, J:; Müller, J.; Müller, M.; Arnold, K.; Arnhold, J. The signal-to-noise ratio as the measure for the quantification of lysophospholipids by matrix-assisted laser desorption/ ionisation time-of-flight mass spectrometry. Analyst, 2001, 126, 1042-50.
48. Hong, C.-W.; Song, D.-K. Immunomodulatory actions of lysophosphatidylcholine. Biomol. Ther., 2008, 16, 69-76.
49. 2 inhibition and neutralization of free radicals by antioxidants - A new role as anti-inflammatory molecule. Curr. Top. Med. Chem., 2007, 7, 765-77.
50. Messner, M.C.; Albert, C.J.; McHowat, J.; Ford, D.A. Identification of lysophosphatidylcholine-chlorohydrin in human atherosclerotic lesions. Lipids, 2008, 43, 243-9.
51. Chun, J.; Goetzl, E.J.; Hla, T.; Igarashi, Y.; Lynch, K.R.; Moolenaar, W.; Pyne, S.; Tigyi, G. International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol. Rev., 2002, 54, 265-9.
52. Noguchi, K.; Ishii, S.; Shimizu, T. Identification of p2y9/GPR23 as a novel G proteincoupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J. Biol. Chem., 2003, 278, 25600-6.
53. Ishii, I.; Fukushima, N.; Ye, X.; Chun, J. Lysophospholipid receptors: signaling and biology. Annu. Rev. Biochem., 2004, 73, 321.
54. Anliker, B.; Chun, J. Cell surface receptors in lysophospholipid signaling. Semin. Cell Dev. Biol., 2004, 15, 457-65.
55. Müller, J.; Petković, M.; Schiller, J.; Arnold, K.; Reichl, S.; Arnhold, J. Effects of lysophospholipids on the generation of reactive oxygen species by fMLP- and PMA-stimulated human neutrophils. Luminescence, 2002, 17, 141-9.
56. Lin, P.; Welch, E.J.; Gao, X.P.; Malik, A.B.; Ye, R.D. Lysophosphatidylcholine modulates neutrophil oxidant production through elevation of cyclic AMP. J. Immunol., 2005, 174, 2981-9.
57. Frasch, S.C.; Zemski-Berry, K.; Murphy, R.C.; Borregaard, N.; Henson, P.M.;Bratton, D.L. Lysophospholipids of different classes mobilize neutrophil secretory vesicles and induce redundant signaling through G2A. J. Immunol., 2007, 178, 6540-8.
58. Englberger, W.; Bitter-Suermann, D.; Hadding, U. Influence of lysophospholipids and PAF on the oxidative burst of PMNL. Int. J. Immunopharmacol., 1987, 9, 275-82.
59. Yan, J.J.; Jung, J.S.; Lee, J.E.; Lee, J.; Huh, S.O.; Kim, H.S.; Jung, K.C.; Cho, J.Y.; Nam, J.S.; Suh, H.W.; Kim, Y.H.; Song, D.K. Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat Med., 2004, 10, 161-7.
60. Zurgil, N.; Afrimzon, E.; Shafran, Y.; Shovman, O.; Gilburd, B.; Brikman, H.; Shoenfeld, Y.; Deutsch, M. Lymphocyte resistance to lysophosphatidylcholine mediated apoptosis in atherosclerosis. Atherosclerosis, 2007, 190, 73-83.
61. Birgbauer, E.; Chun, J. New developments in the biological functions of lysophospholipids. Cell. Mol. Life Sci., 2006, 63, 2695-701.
62. Tome, M.E.; Lutz, N.W.; Briehl, M.M. Overexpression of catalase or Bcl-2 delays or prevents alterations in phospholipid metabolism during glucocorticoid-induced apoptosis in WEHI7.2 cells. biochim. Biophys. Acta, 2003, 1642, 149-62.
63. Podo, F. Tumour phospholipid metabolism. NMR Biomed., 1999, 12, 413-39.
64. Ngwenya, B.Z.; Yamamoto, N. Activation of peritoneal macrophages by lysophosphatidylcholine. Biochim Biophys Acta, 1985, 839, 9-15.
65. Ryborg, A.K.; Deleuran, B.; Sogaard, H.; Kragballe, K. Intracutaneous injection of lysophosphatidylcholine induces skin inflammation and accumulation of leukocytes. Acta Derm. Venereol., 2000, 80, 242-6.
66. Stiko, A.; Regnström, J.; Shah, P.K.; Cercek, B.; Nilsson, J. Active oxygen species and lysophosphatidylcholine are involved in oxidized low density lipoprotein activation of smooth muscle cell DNA synthesis. Arterioscler. Thromb. Vasc. Biol., 1996, 16, 194-200.
67. Kishimoto, T.; Soda, Y.; Matsuyama, Y.; Mizuno, K. An enzymatic assay for lysophosphatidylcholine concentration in human serum and plasma. Clin. Biochem., 2002, 35, 411-6.
68. 2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation, 2007, 115, 2715-21.
69. Sasagawa, T.; Suzuki, K.; Shiota, T.; Kondo, T.; Okita, M. The significance of plasma lysophospholipids in patients with renal failure on hemodialysis. J. Nutr. Sci. Vitaminol. (Tokyo), 1998, 44, 809-18.
70. 2 and effects of simvastatin treatment. Atherosclerosis, 2008, 196, 931-6.
71. Okita, M.; Gaudette, D.C.; Mills, G.B.; Holub, B.J. Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine (lysoPC) in ovarian cancer patients. Int. J. Cancer, 1997, 71, 31-4.
72. Mehta, D.; Gupta, S.; Gaur, S.N.; Gangal, S.V.; Agrawal, K.P. Increased leukocyte phospholipase A2 activity and plasma lysophosphatidylcholine levels in asthma and rhinitis and their relationship to airway sensitivity to histamine. Am. Rev. Respir. Dis., 1990, 142, 157-61.
73. Drobnik, W.; Liebisch, G.; Audebert, F.X.; Fröhlich, D.; Glück, T.; Vogel, P.; Rothe, G.; Schmitz, G. Plasma ceramide and lysophosphatidylcholine inversely correlate with mortality in sepsis patients. J. Lipid Res., 2003, 44, 754-61.
74. Chen, L.; Liang, B.; Froese, D.E.; Liu, S.; Wong, J.T.; Tran, K.; Hatch, G.M.; Mymin, D.; Kroeger, E.A.; Man, R.Y.; Choy, P.C. Oxidative modification of low density lipoprotein in normal and hyperlipidemic patients: effect of lysophosphatidylcholine composition on vascular relaxation. J. Lipid Res., 1997, 38, 546-53.
75. Zhang, B.; Fan, P.; Shimoji, E.; Itabe, H.; Miura, S.; Uehara, Y.; Matsunaga, A.; Saku, K. Modulating effects of cholesterol feeding and simvastatin treatment on plateletactivating factor acetylhydrolase activity and lysophosphatidylcholine concentration. Atherosclerosis, 2006, 186, 291-301.
76. McHowat, J.; Corr, P.B. Thrombin-induced release of lysophosphatidylcholine from endothelial cells. J. Biol. Chem., 1993, 268, 15605-10.
77. Murphy, A.A.; Santanam, N.; Morales, A.J.; Parthasarathy, S. Lysophosphatidyl choline, a chemotactic factor for monocytes/ T-lymphocytes is elevated in endometriosis. J. Clin. Endocrinol. Metab., 1998, 83, 2110-3.
78. Ryborg, A.K.; Gron, B.; Kragballe, K. Increased lysophosphatidylcholine content in lesional psoriatic skin. J. Dermatol., 1995, 133, 398-402.
79. Glander, H.-J.; Schiller, J.; Süß, R.; Paasch, U.; Grunewald, S.; Arnhold, J. Deterioration of spermatozoal plasma membrane is associated with an increase of sperm lyso-phosphatidylcholines. Andrologia, 2002, 34, 360-6.
80. Lindahl, M.; Tagesson, C. Selective inhibition of group II phospholipase A2 by quercetin. Inflammation, 1993, 17, 573-82.